IN BRIEF: hVIVO interim revenue grows; in line with expectations
26th Jul 2023 14:29
hVIVO PLC - London-based specialist contract research organisation providing testing for infectious and respiratory vaccines - Says revenue in the six months to June 30 grew by 52% to GBP27.3 million from GBP18.0 million a year prior. Earnings before interest, depreciation and amortisation margin is around 19%, higher than 13% the year before. Adds order book at June 30 was GBP78 million, up 11% from GBP70 million in the first half of 2022. Notes full-year revenue remains in line with expectations of GBP53 million, as well as Ebitda margins in mid to high teens. Read More